| Company/Division name | Lupin Pharmaceuticals |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Total number of jobs (added or to be added): | 200 |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2030 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 250 |
| Country(ies) from which reshored: | India |
| City reshored to: | Coral Springs |
| State(s) reshored to: | FL |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | pharmaceuticals |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption |
| What domestic positive factors made reshoring more attractive? | Government Incentives |
